Document is current
Any future updates will be listed below
-
Authors
Fitzgibbon, James J.
Ruan, Mengyuan
Heindel, Patrick
Appah-Sampong, Abena
Dey, Tanujit
Khan, Ali
Hentschel, Dirk M.
Ozaki, C. Keith
Hussain, Mohamad A.
-
Funding
Funding for this research was provided by:
American Heart Association (23DIVSUP1069428)
Departmental Grants at Brigham and Women’s Hospital
- License Information
-
More Information
Article History
Received: 8 May 2024
Accepted: 26 May 2025
First Online: 1 June 2025
Declarations
:
: JJF, MR, PH, AAS, TD, AK—Nothing to disclose. DMH—Bard BD, consultant; BluegrassVascular, consultant; Laminate Medical, consultant; Medtronic, consultant; Merit, consultant; Sanifit, consultant; Shifamed, consultant; Surmodics, consultant; VenoStent, consultant; VenovaMed, consultant; Humacyte Inc, advisory board; Nephrodite, advisory board CKO- Humacyte, Inc, advisory board, consultant; Laminate Medical Technologies, consultant; Mitobridge, Inc., consultant and joint research venture MAH- Vascular Therapies (ACCESS-2 Trial), Humacyte, Inc (V-012 Trial; consulting).
